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Marcus D LancéAbstract
Thrombosis and hemorrhage are major contributors to morbidity and mortality. The traditional laboratory tests do
not supply enough information to diagnose and treat patients timely and according to their phenotype. Global
hemostasis tests might improve this circumstance. The viscoelastic tests (ROTEM/TEG) demonstrated to ameliorate
treatment of acute hemorrhage in terms of decreased amount of transfusion and lowered costs. Thrombin
generation measurement is indicative for thrombosis and might also become an important tool in managing
hemorrhage. While the clot waveform analysis is less well known it could be of worth in staging sepsis patients,
early detection of DIC and also in diagnosis and treatment monitoring of hemophiliac patients. Although in
different degree all three methods still need more background, standardization and acceptance before a wide
clinical application.
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Thrombosis and hemorrhage contribute to a large amount
of death in terms of ischemic heart disease, stroke and
traumatic injuries [1]. For that reason timely diagnosis,
risk stratification and monitoring of treatment with ani-
thrombotics or hemostatic agents becomes crucial. The
traditional coagulation tests (aPTT and PT/INR) have
been developed while discovering the coagulation cascade
and contributed to our current understanding. The tests
have been standardized for monitoring therapy (i.e. vita-
min K antagonist-INR and heparin-aPTT). Moreover they
have a longstanding position in diagnosis and manage-
ment of factor deficiencies including hemophilia and are
licensed by many authorities (e.g. FDA) for this purpose.
Although they are recommend for management of acute
(acquired) hemorrhage these tests need some laboratory
turnaround time and may not reflect the complexity of
the hemostatic impairment. In this light the traditional co-
agulation tests (aPTT and PT/INR) are scrutinized for this
clinical applicability. On one hand these tests never wereCorrespondence: marcus.lance@mumc.nl
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unless otherwise stated.developed nor were evaluated for predicting bleeding risk
and treatment of acute bleeding patients [2,3]. That is why
current guidelines consider the use of global hemostatic
coagulation tests in management acute hemorrhage [4,5].
On the other hand the reporting of these assays mostly
stops at the moment the so-called thrombin burst starts.
That is to say the traditional tests inform on the initiation
of clotting but not the hemostatic capacity in terms of clot
formation and maximal thrombin generation although
this is technical possible (e.g. clot waveform analysis).
Yet, since the early phase of coagulation research there
were reports on more global assays, which nowadays
gain more attention. In 1948 Hartert presented the first
viscoelastic test, which he called thromboelastography
[6]. Little later in 1953 it was MacFarlane and Biggs who
reported a measurement of thrombingeneration in blood
[7]. However at that moment both techniques were very
time and work intensive which made them not applicable
in clinical practice.
An ideal coagulation test should be easily to perform
and quickly to obtain while giving high reliable and robust
results. The assay should allow an accurate estimation of
the thrombotic risk and the risk of bleeding. Furthermore
it should employ flow conditions, endothelial interaction,an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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such as pH and temperature. In short such an ideal co-
agulation test currently does not exist. However there
are attempts to develop assays, which fulfill these re-
quests, at least partially.
The present review describes the viscoelastic tests
(TEG/ROTEM), thrombin generation test (TGT) and
the clot waveform analysis (CWA) as global clotting test
giving some background information, clinical applica-
tions and finally information on their limits.
Viscoelatic tests (thromboelastography,
thromboelastometry)
Hartert presented in 1948 a method to monitor the dy-
namics of the complete coagulation process in whole
blood, which he called thromboelastography [6]. In the
original method fresh whole blood was triggered with a
coagulation activator of the contact pathway (celite) and
put into a cup. Then a torsion wire was brought into the
mixing cup, which was continuously turned with an
angle of 4∘45’. As the gradual formation of the clot
strength increases the movement of the torsion wire
damps until it becomes almost fixed in the moment of
maximal clot stability. Tracings of the movement over
time reflect the characteristic graph, from which the
start of clot formation, and maximal stability of the clot
can be read (Table 1). The method also detects gradual
resolution of the clot due to fibrinolysis. Soon after its
description, this viscoelastic method was criticized to be
too global. Another criticism was its high sensitivity to
external vibrations and the lack of detecting single factor
deficiencies [6,8,9]. Moreover the test was time and work
intensive, which discouraged a wide spreading of the
method. After introducing improvements to allow auto-
mation of the technique and implementation of a myriad
of trigger reagents, which give information on the ex-
trinsic pathway (tissue factor), the effects of the fibrin
fraction on clot forming (platelet inhibitor-cytochalasin
D/abciximab) but also on specific questions such as hep-
arin effect (heparinase test) or resistance to lysis (aprotininTable 1 Thromboelastography parameters
Variable TEG ROTEM
From start until 2 mm baseline R Clotting time (CT)
From 2–20 mm above baseline K Clot formation
time (CFT)
Alpha angle (°) Slope Angle of tangent
at 2 mm
Between R&K
Maximum strength Maximal amplitude Maximal clot
firmness
(MA) (MCF)
Clot lysis (CL) at minutes CL 30, CL 60 LY30, LY 60test) thrombelastography has become a method with a
wider range of applications [10]. In the mid 1980ties, the
method was picked up as a potential bedside point-of-care
test for monitoring hemostasis during liver transplantation
and cardiac surgery [11,12].
Currently, two (semi)automated commercial devices are
on the market. The thromboelastometry (ROTEM-analyzer,
TEM international, Muenchen, Germany) instrument uses
a fixed cup with a pin that is rotating. The other thrombe-
lastography (TEG-analyzer, Haemonetcis Corp., Braintree,
MA, United States) system makes use of the classical
method with rotating cup [13]. While being designed as
kinetic tests, either method effectively measures the cap-
acity of the coagulation process in terms of maximal fibrin
clot formation [14]. During the last years, these tests have
been shown to be suitable for detecting and treating coag-
ulopathy in trauma care, cardiac surgery and liver trans-
plantation, particularly in patients were fibrinogen levels
are low [15-17]. Thromboelastography seems to become
an important tool in detecting coagulopathies and guiding
hemostatic therapy at the bedside, especially in the oper-
ation theater [4]. It has been shown to detect excess hep-
arin effect, but also to catch signs of hemodilution in
cardiac surgery. Treatment upon these results could be
shown to save transfusion of blood products and reduce
costs [18]. As a point of care device it may also monitor
hemorrhage and control therapy during obstetric surgery,
at the emergency department, and at the intensive care
unit [13,19]. Recently, there are reports on the efficacy of
the device when used in pediatric craniosynothesis sur-
gery. Here the need for transfusion of fresh frozen plasma
and platelet transfusion could be dramatically reduced
[20]. Although the thromboelastography is able to detect
hypercoagulable situations it is not frequently used to pre-
dict thrombosis rather to tailor antithrombotic therapy.
This might also be due to the fact that thromboelastogra-
phy does not reflect the effects of LMWH’s and (new) oral
anticoagulants completely.
As in any assay there are some blind spots in this
method. Platelet dysfunction either inherited or drug
induced will not be detected. Another shortcoming is
the insensitivity to detect the effects of von Willebrand
Factor, which is involved in the initiation of clot form-
ing. Finally, factor XIII, which is mainly responsible for
stabilization of the fibrinogen network, is also not ad-
equately displayed [21,22]. Some of these shortcomings
might be overcome by spiking samples with platelet ac-
tivators or specific antibodies [22]. Finally there are
still some concerns about standardization of the assays.
Recently an investigation on quality control and assur-
ance showed a wide variation of TEM results between
different centers when comparing plasma sample analysis.
Hereupon a working group was set up to homogenize
the variability of this test [23,24]. However, the variability
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management [25,26].
Thrombin generation
MacFarlane and Biggs described in 1953 the thrombin
measurement in whole blood [7]. In the same issue of
the journal Pitney and Dacie did so in plasma [27]. Al-
though the authors could identify hemophiliac patients
the test was very work and time intensive, because the
measurement had to be done by continuously subsamp-
ling. To overcome this problem many years later Hemker
and Beguin developed a method using a chromogenic sub-
strate. Unfortunately the selected substrate exhausted
quickly and did not reflect the complete amount of
thrombin generating. Moreover it inhibited the physio-
logical feedback loops of thrombin so it interfered
strongly with the measurement. Hemker improved the
assay by changing to another substrate (MeO-mal-Aib-
Arg-pNA). However the reaction product of this sub-
strate had to be determined by optical measures that
only could be performed in defibrinated plasma. Shortly
hereafter the same group replaced the chromogenic
substrate by a fluoroscopic agent (Z-Gly-Gly-Arg),
which was bound to 7-amino-4-methylcoumarin. With
this substrate the read out could be done automatically
by monitoring the fluorescence signal. By comparing it
with a calibrator of known thrombin activity the devel-
opment of the calibrated automated thrombin gener-
ation (CAT) was possible [28]. Next to this system there
are several thrombin generation tests commercially
available, which rely on fluorogenic or chromogenic
principles (manual and automated fluorogenic assay by
Technclone, chromogenic assay by Dade Behring and
customized tests such as the Novel Hemostasis Assay
from the Radboud University Medical Centre, Nij-
megen, The Netherlands).
In general thrombin generation tests (TGT) uses some
trigger to imitate vessel wall damage (e.g. tissue factor).
In platelet poor plasma (PPP) procoagulant phospholipids
(in general about 4 μM) amplify the effects of tissue factor
[29]. Depending on the question of the test the amount of
added TF may reflect different kinds of factor composi-
tions. That means with large amounts (>10pM) TF factor
VIII, IX and XI are bypassed, but between 2 and 5 pM TG
depends on factor VIII and IX and at even lower con-
centrations factor XI might become more important
[30]. In contrast when using platelet rich plasma (PRP)
the platelets take the role of phospholipids over as amp-
lifying surface. By this the reaction reflects the interplay
of platelet activation and plasmatic coagulation. The
most relevant parameters deriving from the thrombin
generation tests are the lag-time (time to start), the time
to peak, the peak height, and the endogenous thrombin
potential (ETP) [28].After its initial use as a research tool the TGT shows in-
creased thrombin generation in thrombophilic states such
as venous thrombosis due to deficiency (e.g. AT, protein C
or S, deficiency) as well as due to APC-resistance and the
antiphospholipid syndrome [31,32]. However this depends
on activator and additives (e.g. thrombomodulin, activated
protein C). Moreover is increased thrombin generation as-
sociated with arterial thrombosis such as ischemic stroke,
but also with acute coronary syndromes [33,34]. In these
scenarios assessment of TG could be helpful guiding
therapy with antithrombotics while trying to avoiding
bleeding. Finally thrombin generation gives important
information in hemorrhagic disease either inherited
(hemophila A and B) or acquired (factor deficiency, VKA-
therapy) [33,35]. In hemophiliac patients the TGT might
describe the bleeding tendency and so the risk of bleeding
better than the traditional tests. Particularly the bypassing
therapy of hemophiliacs with inhibitors might improve,
but this is still matter of debate [36-39].
When compared to the viscoelastic tests, which asses
the fibrin clot formation in general, the TGT could give
more information on the hemostatic capacity in total,
because the generation of thrombin does not stop at the
moment when the fibrin clot has been generated [28]. In
a recent clinical study it could be shown that TGT gives
additive information managing bleeding patients [40].
Bosch et al. recently demonstrated the additive value of
the TGT when assessing patients undergoing cardiac
surgery. The authors could show that the TGT was able
to predict bleeding [41].
However the TGT is performed in platelet poor
plasma (PPP) and/or platelet rich plasma (PRP), which
needs time for preparing and makes this method not
suitable for quick diagnosis. A more recent development
is the whole blood thrombin generation test, which al-
lows the presence of erythrocytes and other blood cells.
This may be an advantage because the blood cells con-
tribute to coagulation in vivo, which may be underesti-
mated in plasma TG. Additionally using whole blood
saves time because the step of spinning the blood is not
needed. This might accelerate the analysis and makes
this test suitable as a bedside test. However this is still a
matter of research [42].
Of course there are some disadvantages of the
TGT, too. Major drawback was the duration of the test
(e.g. CAT), which makes it not suitable for emergency
cases. On the other hand the assay is not enough stan-
dardized for broad clinical use, which still hampers its
approval as routine clinical tool. There is large variance
due to preanalytic variables and there is a lack of reference
ranges for the specific conditions (kind and amount of
trigger substances) [43,44]. Still there is debate about the
need to use inhibitors of the contact activation pathway
(e.g. corn trypsin inhibitor), because a factor XII pathway
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the results [45].
Clot waveform analysis (CWA)
Principally clot waveform analysis (CWA) is based on
the traditional aPTT assay. It is a technique reported by
Braun and co-workers who assessed the aPTT and PT
with light transmission [46]. Yet, the registration is
photo-optically and the read out is prolonged, which
creates a graph registered over time instead of the clot-
ting time known from the aPTT. The graph is comput-
erized and the first and second derivatives are added to
the final plot. The tracing against the time should reflect
the whole process of clot formation and clot lysis. For
better standardization it seems important that the assay
needs some specific reagents, which do not interfere
with light transmission/absorption [47].
The parameters are given as the transmittance trace,
its first derivative, which gives information on the velocity
of coagulation and its second derivative, which informs
about the acceleration and deceleration of coagulation.
In each of the graphs three phases are distinguished: a
pre-coagulation phase, a coagulation phase and a post-
coagulation phase with set of ten parameters each [48].
Although the method still needs standardization there
are a couple of possible clinical applications.
In the first instance this test was used to monitor the
course of disseminated intravascular coagulation, a dis-
ease, which frequently was seen in critically ill patients.
The findings were independently from standard aPTT
measurements. Using this test as a global assessment
tool a DIC might be diagnosed with a high specificity
(97.6%) and sensitivity (98%) [49,50]. Moreover this
assay could even detect the DIC earlier than conventional
methods in up to 19% of the cases. For that reason the test
is recommended by the guidelines for diagnosis and treat-
ment of DIC [51].
Besides these findings the test seems sensitive to even
mild factor deficiencies (FXII, X, IX, VII, V and II). In
this light the assay gives information on hemophiliacs.
It might help to distinguish between hemophilia A
and B. Moreover the assay gives information on the
clinical phenotype with regard of bleeding tendency.
Doing so it might help monitoring treatment of these
patients with factor concentrates but also with bypassing
agents [52].
Some authors challenged the test in critically ill pa-
tients suffering from sepsis. Here they could show that
the severity and the prognosis of sepsis may be pre-
dicted by the CWA [53,54]. The CWA results were
more accurate than standard inflammation parameters
(C-reactive protein and procalcitonin) [55]. These find-
ings were recently confirmed in a pediatric population
suffering from meningococcal infection [56].Although the CWA is inexpensive and easily to per-
form there is some disadvantage impeding its widely use.
Currently there are only two systems, which are able to
assess the light transmittance or absorbance tracings.
However analyzers, which work with the same principles
should be able to create the graphs after updating with
the necessary software. Another drawback is the obliga-
tion to use clear reagents, which do not interfere with
the light beam. This might also form a problem in case
of colored plasma (hyperbilirubinemia, hyperlipidemia
or hemolysis) [47]. Due to the fact that there is not
much experience with this assay the parameters seem
quite unknown and there is not much literature with re-
gard to clinical validation.
Conclusions
Our traditional coagulation tests do not cover all informa-
tion the clinician needs to diagnose and treat thrombophi-
lia, hemorrhage and inherited coagulation disorders. Global
coagulation assays such as viscoelastic tests (TEM/TEG),
thrombin generation test and clot waveform analysis care
several advantages. While the viscoelastic tests proved to
be worthwhile in management of acute hemorrhage, the
thrombin generation test showed to be of use in throm-
bosis (venous and arterial) but also it might be a meaning-
ful instrument in hemostatic therapy. The latter technique
is at the beginning of a broad clinical use. Clot waveform
analysis is even less well known. Although there is reason-
able suspicion that this method might improve diagnosis
and treatment of DIC, sepsis and hemophilia its applica-
tion is not wide spread. Yet, there is need for more clinical
data to support the current evidence.
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